By - Ankit Sethi
- The tax refund would provide funding for continued development of the company’s portfolio of radiopharmaceutical products
- Radiopharm recently announced a two-year partnership with cancer research centre GenesisCare
- The company is set to attend the Jefferies Radiopharma Innovation Summit in New York next month
Australia's oncology space player Radiopharm Theranostics (ASX: RAD) has updated the market on research and development (R&D) tax refund. The company's R&D works during the 2022 financial year have been recognised, and a tax refund of over AU$1.56 million has been released in favour of RAD.
Recently, the company had also informed about its collaboration with GenesisCare for Phase 1 clinical trials of radiopharmaceutical nanobodies in Australia.
RAD's shares traded at AU$0.17 at the time of writing on 28 March 2023.